Lawrence G Hamel Insider Trading $ACRX ACELRX PHARMACEUTICALS INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Lawrence G Hamel.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Lawrence G Hamel. Lawrence G Hamel is Chief Development Officer in ACELRX PHARMACEUTICALS INC ($ACRX).
Lawrence G Hamel in ACELRX PHARMACEUTICALS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Lawrence G Hamel: Chief Development Officer
Holdings: 133,382 shares
Current Value: $400,146
Latest Transaction: Feb 07 2020
$ACRX Market Capitalization: $131.47M
$ACRX Previous Close: $3.00
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Lawrence G Hamel in ACELRX PHARMACEUTICALS INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 1.72 | 100,000 | 172,000 | 100,000 | |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 0.00 | 50,000 | 0 | 133,382 | 83.4 K to 133.4 K (+59.96 %) |
| Nov 04 2019 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.23 | 26,125 | 58,128 | 52,250 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.51 | 100,000 | 251,000 | 100,000 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 0.00 | 50,000 | 0 | 74,371 | 24.4 K to 74.4 K (+205.16 %) |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | D | 2.23 | 5,000 | 11,125 | 21,125 | |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.23 | 26,125 | 58,128 | 26,125 | |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | D | 5.00 | 5,000 | 25,000 | 29,795 | 34.8 K to 29.8 K (-14.37 %) |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 2.23 | 5,000 | 11,125 | 34,795 | 29.8 K to 34.8 K (+16.78 %) |
| Oct 16 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | S | 5.00 | 5,216 | 26,080 | 29,795 | 35 K to 29.8 K (-14.90 %) |
| Sep 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | S | 4.50 | 6,953 | 31,289 | 35,011 | 42 K to 35 K (-16.57 %) |
| Sep 05 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 1.49 | 6,876 | 10,245 | 24,371 | 17.5 K to 24.4 K (+39.30 %) |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.00 | 95,000 | 190,000 | 95,000 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 2.00 | 95,000 | 190,000 | 95,000 | |
| Sep 27 2017 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Sell | S | 0.00 | 13,827 | 0 | 68,504 | 82.3 K to 68.5 K (-16.79 %) |
| Apr 11 2017 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | D | 1.20 | 9,122 | 10,946 | 0 | |
| Apr 11 2017 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 0.00 | 6,879 | 0 | 80,354 | 73.5 K to 80.4 K (+9.36 %) |
| Apr 11 2017 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 1.20 | 9,122 | 10,946 | 73,475 | 64.4 K to 73.5 K (+14.17 %) |
| Feb 09 2017 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.00 | 79,500 | 238,500 | 79,500 | |
| Feb 18 2016 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.40 | 70,000 | 238,000 | 70,000 | |
| Mar 06 2012 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Payment of Exercise | F | 2.91 | 1,717 | 4,996 | 13,643 | 15.4 K to 13.6 K (-11.18 %) |
| Feb 09 2012 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.39 | 51,319 | 173,971 | 51,319 | |
| Feb 09 2012 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.39 | 51,319 | 173,971 | 51,319 | |
| Sep 08 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Payment of Exercise | F | 3.10 | 1,539 | 4,771 | 15,360 | 16.9 K to 15.4 K (-9.11 %) |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.45 | 11,000 | 37,950 | 11,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.45 | 20,000 | 69,000 | 20,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 0.00 | 16,899 | 0 | 16,899 | 0 to 16.9 K |
Page: 1